# US 2010/0167980 A1 · Prolyl Endopeptidase Inhibitors For Reducing or Preventing Neutrophilic Inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167980 A1
- Document ID: US20100167980A1
- Status: Published application
- Kind: A1
- Application number: 12/601,216
- Filed: 2008-05-21
- Published: 2010-07-01
- Earliest claimed: 2007-05-21
- Assignees: The UAB Research Foundation
- Inventors: J. Edwin Blalock; Uros V. Djekic; Patricia L. Jackson; Amit Gaggar; Brett Noerager; Philip J. O'Reilly
- Web page: https://patentgrep.com/patent/US20100167980A1

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for reducing or preventing neutrophilic inflammation in a subject comprising selecting a subject with or at risk for neutrophilic inflammation and administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase. Provided herein are also methods for treatment or prevention of diseases associated with neutrophilic inflammation.

## Claims

### Claim 1

A method for reducing or preventing neutrophilic inflammation in a subject comprising:
(a) selecting a subject with or at risk for neutrophilic inflammation; and
(b) administering to the subject an agent that inhibits the expression or activity of prolyl endopeptidase, wherein the agent that inhibits the expression or activity of prolyl endopeptidase is selected from the group consisting of a proline derivative, a pyrrolidineamide derivative, a prolinal derivative, a sulfated chitooligosaccharide, a plant phenolic, eurystatin, an inhibitory peptide, and an inhibitory nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is S17092.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the agent is a plant phenolic.

### Claim 5 (depends on 4)

The method of claim 4, wherein the plant phenolic is selected from the group consisting of 1,2,3-trigalloyl glucopyranoside, 1,2,6-trigalloyl glucopyranoside, 1,2,3,4,6-pentagalloyl gluco-pyranoside, 1,2,6-trigalloyl alloside, 1,3,6-trigalloyl alloside, 1,2,3,6-tetragalloyl alloside, acetonyl geraniin, corilagin, elaeocarpusin, euphorscopin, geraniin, helioscopin B, helioscopinin A, helioscopinin B, jolkinin, macranganin, rugosin E, supinanin, and teracatain.

### Claim 6 (depends on 1)

The method of claim 1, wherein the agent is Z-prolyl prolinal or JTP-4819.

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent is an inhibitory peptide.

### Claim 8 (depends on 7)

The method of claim 7, wherein the inhibitory peptide is SNA-115 or SNA-115T.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the agent is an inhibitory nucleic acid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inhibitory nucleic acid is selected from the group consisting of an antisense molecule, aptamer, ribozyme, triplex forming molecule, short interfering RNA (siRNA), and external guide sequence.

### Claim 12 (depends on 1)

The method of claim 1, wherein the agent is administered by oral inhalation, nasal inhalation, or intranasal mucosal administration.

### Claim 13 (depends on 1)

The method of claim 1, wherein the subject has or is at risk for a disease associated with neutrophilic inflammation, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pulmonary transplantation rejection, chronic bronchitis, emphysema, bronchiectasis, bronchiolitis obliterans syndrome (BOS), interstitial pneumonia, and pulmonary fibrosis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject has or is at risk for a disease associated with neutrophilic inflammation, wherein the disease is bacterial infection or viral infection.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bacterial infection is a bacterial lung infection.

### Claim 16 (depends on 14)

The method of claim 14, wherein the viral infection is a viral lung infection.

### Claim 17 (depends on 13)

The method of claim 13, wherein the disease is COPD.

### Claim 18 (depends on 13)

The method of claim 13, wherein the disease is cystic fibrosis.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of a matrix metalloprotease (MMP) inhibitor, an anti-inflammatory agent, an anti-microbial agent, and an anti-viral agent.

### Claim 20 (depends on 19)

The method of claim 19, wherein the second therapeutic agent is a matrix metalloprotease (MMP) inhibitor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the matrix metalloprotease is MMP-8 or MMP-9.

### Claim 22

(canceled)

### Claim 23

A method of determining whether a subject has neutrophilic inflammation or a disease associated with neutrophilic inflammation, comprising:
(a) obtaining a biological sample from the subject; and
(b) determining the level of expression or activity of PE in the sample, wherein an increase in expression or activity of PE as compared to a control indicates the subject has neutrophilic inflammation or a disease associated with neutrophilic inflammation.

### Claim 24 (depends on 23)

The method of claim 23, further comprising administering to the subject an agent that inhibits the expression or activity or prolyl endopeptidase if the subject has neutrophilic inflammation or a disease associated with neutrophilic inflammation, wherein the agent that inhibits the expression or activity of prolyl endopeptidase is selected from the group consisting of a proline derivative, a pyrrolidineamide derivative, a prolinal derivative, a sulfated chitooligosaccharide, a plant phenolic, eurystatin, an inhibitory peptide, and an inhibitory nucleic acid.

### Claim 25

(canceled)

### Claim 26 (depends on 23)

The method of claim 23, wherein the biological sample is a biological fluid.

### Claim 27 (depends on 26)

The method of claim 26, wherein the biological fluid is selected from the group consisting of serum, sputum and lung lavage.

### Claim 28 (depends on 23)

The method of claim 23, wherein the determining step is carried out using an immunological method.

### Claim 29

(canceled)

### Claim 30 (depends on 24)

The method of claim 24, wherein the agent is S17092.

### Claim 31

(canceled)

### Claim 32 (depends on 24)

The method of claim 24, wherein the agent is a plant phenolic.

### Claim 33 (depends on 32)

The method of claim 32, wherein the plant phenolic is selected from the group consisting of 1,2,3-trigalloyl glucopyranoside, 1,2,6-trigalloyl glucopyranoside, 1,2,3,4,6-pentagalloyl gluco-pyranoside, 1,2,6-trigalloyl alloside, 1,3,6-trigalloyl alloside, 1,2,3,6-tetragalloyl alloside, acetonyl geraniin, corilagin, elaeocarpusin, euphorscopin, geraniin, helioscopin B, helioscopinin A, helioscopinin B, jolkinin, macranganin, rugosin E, supinanin, and teracatain.

### Claim 34 (depends on 24)

The method of claim 24, wherein the agent is Z-prolyl prolinal or JTP-4819.

### Claim 35 (depends on 24)

The method of claim 24, wherein the agent is an inhibitory peptide.

### Claim 36 (depends on 35)

The method of claim 35, wherein the inhibitory peptide is SNA-115 or SNA-115T.

### Claim 37

(canceled)

### Claim 38 (depends on 24)

The method of claim 24, wherein the agent is an inhibitory nucleic acid.

### Claim 39 (depends on 38)

The method of claim 38, wherein the inhibitory nucleic acid is selected from the group consisting of an antisense molecule, aptamer, ribozyme, triplex forming molecule, short interfering RNA (siRNA), and external guide sequence.
